

Table 4. *T*-test for difference in means of maximum percentage clozapine differences.

| Binary groups | Maximum percentage difference compared to 12-hour values | | | | | Maximum percentage change across the 12-hour time-point | | | | |
|-------------------------------------|---|-------------|----------|-------------|--------------------------------|--|-------------|----------|-------------|-------------------|
| | Group yes | | Group no | | <i>P</i> ^a value | Group yes | | Group no | | <i>P</i> value |
| | n | Mean | n | Mean | | n | Mean | n | Mean | |
| Male gender | 26 | 21.8 ± 10.8 | 19 | 17.5 ± 8.7 | 0.1488 | 25 | 17.4 ± 10.6 | 20 | 17.0 ± 9.3 | 0.8913 |
| Age ≥ 45 years | 21 | 23.2 ± 11.5 | 24 | 17.2 ± 7.9 | 0.0548 | 21 | 20.3 ± 10.9 | 24 | 14.5 ± 8.3 | 0.0468* |
| Smoker | 17 | 24.1 ± 12.6 | 28 | 17.5 ± 7.4 | 0.0806 | 16 | 16.8 ± 10.5 | 29 | 17.5 ± 9.8 | 0.8265 |
| CRP ≥ 5 mg/l | 16 | 20.2 ± 11.9 | 29 | 19.8 ± 9.2 | 0.9319 | 15 | 17.7 ± 8.7 | 30 | 17.0 ± 10.6 | 0.8383 |
| Chronic leukocytosis | 16 | 22.4 ± 12.7 | 25 | 19.1 ± 8.4 | 0.5106 | 15 | 18.7 ± 9.6 | 26 | 17.0 ± 10.1 | 0.6097 |
| Chronic basophilia | 1 | 53.0 ± N.A. | 40 | 19.6 ± 9.1 | 0.0314* | 1 | 39.1 ± N.A. | 40 | 17.1 ± 9.3 | 0.0251* |
| Chronic eosinopenia | 18 | 18.2 ± 8.8 | 23 | 22.1 ± 11.3 | 0.2358 | 19 | 18.4 ± 10.1 | 22 | 17.0 ± 9.8 | 0.6549 |
| Chronic lymphocytosis | 3 | 28.0 ± 21.3 | 38 | 19.8 ± 9.2 | 0.3568 | 3 | 22.2 ± 17.7 | 38 | 17.3 ± 9.3 | 0.4154 |
| Chronic lymphopenia | 1 | 30.2 ± N.A. | 40 | 20.1 ± 10.3 | 0.3134 | 1 | 21.8 ± N.A. | 40 | 17.5 ± 9.9 | 0.6760 |
| Chronic monocytosis | 4 | 34.5 ± 15.8 | 37 | 18.9 ± 8.6 | 0.0190* | 3 | 28.9 ± 8.8 | 38 | 16.8 ± 9.4 | 0.0368* |
| Chronic neutrophilia | 13 | 24.3 ± 13.3 | 28 | 18.6 ± 8.3 | 0.2113 | 12 | 16.9 ± 11.4 | 29 | 17.9 ± 9.3 | 0.7638 |
| Chronic neutropenia | 1 | 12.6 ± N.A. | 40 | 20.6 ± 10.4 | 0.4890 | 1 | 17.5 ± N.A. | 40 | 17.6 ± 10.0 | 0.9890 |
| 1 daily dosing of clozapine | 29 | 19.3 ± 9.9 | 16 | 21.3 ± 10.6 | 0.6403 | 29 | 17.8 ± 9.4 | 16 | 16.2 ± 11.0 | 0.6013 |
| Co-medicated with ADs ^b | 20 | 18.9 ± 8.5 | 25 | 20.9 ± 11.3 | 0.6458 | 21 | 16.2 ± 9.0 | 24 | 18.1 ± 10.7 | 0.5217 |
| Co-medicated with ACs ^b | 8 | 17.2 ± 8.5 | 37 | 20.6 ± 10.4 | 0.4134 | 8 | 12.4 ± 6.9 | 37 | 18.3 ± 10.2 | 0.1307 |
| Co-medicated with PPIs ^b | 8 | 20.1 ± 7.9 | 37 | 20.0 ± 10.6 | 0.7775 | 9 | 18.5 ± 5.0 | 36 | 16.9 ± 10.8 | 0.6873 |
| Co-medicated with HCs ^b | 6 | 13.3 ± 5.0 | 13 | 19.4 ± 9.5 | 0.1802 | 6 | 18.6 ± 6.9 | 14 | 16.3 ± 10.3 | 0.6205 |

^a *T*-test based on log-transformed percentage differences^b ADs=antidepressants, ACs=anticonvulsants, PPIs= proton pump inhibitors, HCs=hormonal contraceptives* Significant *P* values (two-tailed)